Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional

• Published in: Patient Preference and Adherence
• Main Authors: Johanson,Viktor, Wilson,Benedicte, Abrahamsson,Anna, Jianu,Constantin, Calissendorff,Jan, Wall,Najme, Grønbæk,Henning, Florholmen,Jon, Öhberg,Anders, Granberg,Dan
• Format: Article in Journal/Newspaper
• Language: English
• Published: Dove Press 2012
• Subjects: Patient Preference and Adherence; Norway; Tromsø; St. Olav; North Norway
• Online Access: https://www.dovepress.com/randomized-crossover-study-in-patients-with-neuroendocrine-tumors-to-a-peer-reviewed-fulltext-article-PPA

Viktor Johanson,1 Benedicte Wilson,2 Anna Abrahamsson,3 Constantin Jianu,4 Jan Calissendorff,5 Najme Wall,6 Henning Grønbæk,7 Jon Florholmen,8 Anders Öhberg,9 Dan Granberg101Department of Surgery, Sahlgrenska University Hospital, Göteborg, Sweden; 2Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark; 3Karolinska Institutet, Department of Hepatology, Karolinska University Hospital, Huddinge, Sweden; 4Department of Gastroenterology and Liver Disease, St Olav Hospital, Trondheim, Norway; 5Karolinska Institutet, Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Solna, Sweden; 6Department of Oncology, Linköping University Hospital, Linköping, Sweden; 7Department of Medicine V, Aarhus University Hospital, Aarhus, Denmark; 8Department of Gastroenterology and Nutrition, University Hospital of North Norway, Tromsø, Norway; 9Medical Department, Ipsen AB, Stockholm, Sweden; 10Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, SwedenBackground: Lanreotide Autogel® is supplied in prefilled syringes. Therefore, it is possible for patients with neuroendocrine tumors to use self-/partner-administered injections. The primary objective of this study was to assess the proportion of patients preferring self/partner injections over injections administered by health care professionals, and to describe the impact of self/partner administration on efficacy, safety, and costs.Methods: Of 62 eligible patients, 26 (42%) patients with neuroendocrine tumors treated with a stable dose of lanreotide Autogel 90 mg or 120 mg every 4 weeks agreed to participate in this Phase IV, international, open-label, crossover study, conducted at hospitals in Sweden, Norway, and Denmark. Patients were randomized to two blocks, starting with administration of lanreotide Autogel by either self/partner or a health care professional. Preference for injections administered by self/partner or health care professionals was measured, as well as efficacy, ...